The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit – a clinical review

A review of 10 studies indicates that melatonin and ramelteon may help reduce the incidence and severity of delirium in ICU patients.

• ICU environments are associated with sleep disturbances and circadian rhythm disorders, which may increase delirium risk.
• Melatonin and its receptor agonist, ramelteon, could partially eliminate factors that induce delirium.
• The use of melatonin therapy may also reduce the time patients spend on mechanical ventilation and the need for psychoactive medications.
• A holistic approach addressing sleep disorders may be necessary to mitigate delirium risk factors.
• Further studies with larger participant numbers are needed to confirm the efficacy of melatonin therapy in ICU settings.

AI simplified